Möllerström et al. BMC Cancer 2010, 10:296 http://www.biomedcentral.com/1471-2407/10/296 We gratefully acknowledge the help of Ulric Pedersen in preparing some of the illustrations. Author Details 1Department of Oncology, Institute of Clinical Sciences, Blå stråket 2, University of Gothenburg, SE-413 45 Göteborg, Sweden, 2Pathology section, Department of Pathology, Sahlgrenska University Hospital, Blå stråket 2, University of Gothenburg, SE-413 45 Göteborg, Sweden, 3Department of Oncology, Barngatan 2:2, Lund University Hospital, University of Lund, SE-221 85 Lund, Sweden, 4Division of Clinical Cancer Epidemiology, Department of Oncology, Sahlgrenska Academy, University of Gothenburg, Sweden, 5UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, 6Department of Laboratory Medicine, Center for Molecular Pathology, Lund University, University Hospital MAS, Malmö, Sweden and 7Department of Oncology, Sahlgrenska University Hospital, Blå stråket 2, University of Gothenburg, SE-413 45 Göteborg, Sweden Received: 29 September 2009 Accepted: 16 June 2010 Published: 16 June 2010 TB©hM2isC0ia1Csr0taiMncleöOlripse2ra0nsv1tAar0öic,lam1be0sl:e2t9far6lo;tmlicl:ehndtsiepte:r/iBbwiuowtMewde.dbuinCodemnetrdahcleLndetr.aml.csomft/h1e47C1re-2a4ti0v7e/C10o/m29m6onsAt ributionLicense(ht p:/ creativecommons.org/licenses/by/2.0),whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited. References 1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353:1784-1792. 3. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144. 4. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, et al.: Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008, 9:730-756. 5. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 6. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679. 7. Karlsson E, Delle U, Danielsson A, Olsson B, Abel F, Karlsson P, Helou K: Gene expression variation to predict 10-year survival in lymph-node- negative breast cancer. BMC Cancer 2008, 8:254. 8. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD, Caldas C: A gene- expression signature to predict survival in breast cancer across independent data sets. Oncogene 2006. 9. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10. Mollerstrom E, Delle U, Danielsson A, Parris T, Olsson B, Karlsson P, Helou K: High-resolution genomic profiling to predict 10-year overall survival in node-negative breast cancer. Cancer Genet Cytogenet 2010, 198:79-89. 11. Ryden L, Landberg G, Stal O, Nordenskjold B, Ferno M, Bendahl PO: HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res Treat 2008, 109:351-357. 12. Gehan EA: A Generalized Wilcoxon Test for Comparing Arbitrarily Singly-Censored Samples. Biometrika 1965, 52:203-223. 13. Heymans MW, van Buuren S, Knol DL, van Mechelen W, de Vet HC: Variable selection under multiple imputation using the bootstrap in a prognostic study. BMC Med Res Methodol 2007, 7:33. 14. Heagerty PJ, Zheng Y: Survival model predictive accuracy and ROC curves. Biometrics 2005, 61:92-105. 15. Montagnoli A, Guardavaccaro D, Starace G, Tirone F: Overexpression of the nerve growth factor-inducible PC3 immediate early gene is associated with growth inhibition. Cell Growth Differ 1996, 7:1327-1336. 16. Varnum BC, Reddy ST, Koski RA, Herschman HR: Synthesis, degradation, and subcellular localization of proteins encoded by the primary Page 10 of 11 response genes TIS7/PC4 and TIS21/PC3. J Cell Physiol 1994, 158:205-213. 17. Ficazzola MA, Fraiman M, Gitlin J, Woo K, Melamed J, Rubin MA, Walden PD: Antiproliferative B cell translocation gene 2 protein is down- regulated post-transcriptionally as an early event in prostate carcinogenesis. Carcinogenesis 2001, 22:1271-1279. 18. Kawakubo H, Carey JL, Brachtel E, Gupta V, Green JE, Walden PD, Maheswaran S: Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer. Oncogene 2004, 23:8310-8319. 19. Melamed J, Kernizan S, Walden PD: Expression of B-cell translocation gene 2 protein in normal human tissues. Tissue Cell 2002, 34:28-32. 20. Duriez C, Moyret-Lalle C, Falette N, El-Ghissassi F, Puisieux A: BTG2, its family and its tutor. Bull Cancer 2004, 91:E242-253. 21. Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR, Gudkov AV: A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev 2006, 20:236-252. 22. Lim IK, Lee MS, Lee SH, Kim NK, Jou I, Seo JS, Park SC: Differential expression of TIS21 and TIS1 genes in the various organs of Balb/c mice, thymic carcinoma tissues and human cancer cell lines. J Cancer Res Clin Oncol 1995, 121:279-284. 23. Elmore LW, Di X, Dumur C, Holt SE, Gewirtz DA: Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response. Clin Cancer Res 2005, 11:2637-2643. 24. Cortes U, Moyret-Lalle C, Falette N, Duriez C, Ghissassi FE, Barnas C, Morel AP, Hainaut P, Magaud JP, Puisieux A: BTG gene expression in the p53- dependent and -independent cellular response to DNA damage. Mol Carcinog 2000, 27:57-64. 25. Guardavaccaro D, Corrente G, Covone F, Micheli L, D'Agnano I, Starace G, Caruso M, Tirone F: Arrest of G(1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol Cell Biol 2000, 20:1797-1815. 26. Lim IK, Lee MS, Ryu MS, Park TJ, Fujiki H, Eguchi H, Paik WK: Induction of growth inhibition of 293 cells by downregulation of the cyclin E and cyclin-dependent kinase 4 proteins due to overexpression of TIS21. Mol Carcinog 1998, 23:25-35. 27. Ryu MS, Lee MS, Hong JW, Hahn TR, Moon E, Lim IK: TIS21/BTG2/PC3 is expressed through PKC-delta pathway and inhibits binding of cyclin B1-Cdc2 and its activity, independent of p53 expression. Exp Cell Res 2004, 299:159-170. 28. Hong JW, Ryu MS, Lim IK: Phosphorylation of serine 147 of tis21/BTG2/ pc3 by p-Erk1/2 induces Pin-1 binding in cytoplasm and cell death. J Biol Chem 2005, 280:21256-21263. 29. Tirone F: The gene PC3(TIS21/BTG2), prototype member of the PC3/ BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol 2001, 187:155-165. 30. Chen JG, Yang CP, Cammer M, Horwitz SB: Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003, 63:7891-7899. 31. Islaih M, Halstead BW, Kadura IA, Li B, Reid-Hubbard JL, Flick L, Altizer JL, Thom Deahl J, Monteith DK, Newton RK, Watson DE: Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals. Mutat Res 2005, 578:100-116. 32. Lim YB, Park TJ, Lim IK: B cell translocation gene 2 enhances susceptibility of HeLa cells to doxorubicin-induced oxidative damage. J Biol Chem 2008, 283:33110-33118. 33. Calzolari F, Appolloni I, Tutucci E, Caviglia S, Terrile M, Corte G, Malatesta P: Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. Neoplasia 2008, 10:1373-1382. following 1382 34. Kawakubo H, Brachtel E, Hayashida T, Yeo G, Kish J, Muzikansky A, Walden PD, Maheswaran S: Loss of B-cell translocation gene-2 in estrogen receptor-positive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res 2006, 66:7075-7082. 35. Kaklamani VG, Sadim M, Hsi A, Offit K, Oddoux C, Ostrer H, Ahsan H, Pasche B, Mantzoros C: Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res 2008, 68:3178-3184. 36. Mirza A, Basso A, Black S, Malkowski M, Kwee L, Pachter JA, Lachowicz JE, Wang Y, Liu S: RNA interference targeting of A1 receptor- overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis. Cancer Biol Ther 2005, 4:1355-1360.